Yurt, Y.Ayyıldız, OrhanKarakuş, A.Nursal, Ayşe Feydaİsi, Hilmi2021-09-032021-09-032020Yurt, Y., Ayyıldız, O., A, K., Nursal, A. F. ve İsi, H. (2020). MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia. Bratislava Medical Journal, 121(2), 159-163.0006-9248http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6534&category_id=158&option=com_virtuemarthttps://hdl.handle.net/11468/7429PMID:32115971AIM: In 95 % of Chronic myeloid leukemia (CML) patients, chromosomal translocation resulting in the formation of the Philadelphia (Ph) chromosome (t:9;22) is observed, which in turn leads to the formation of the BCR-ABL fusion gene. MicroRNAs (miRNAs) are a group of small and non-coding RNAs modulating gene expression via binding to the target mRNAs. We aimed to characterize the expression profiles of various miRNAs in different stages of Ph(+) CML patients. METHODS: This case-controlled study was conducted in 75 CML patients and 25 healthy controls. The subjects were categorized into 4 groups; newly diagnosed patients, treatment-response patients, treatment-failure patients, and healthy controls. Expressions of miRNAs was analyzed by RT-PCR. RESULTS: miR-150 expression was downregulated in the treatment failure patients compared to the control group (p = 0.003212) while miRNA 148b expression up-regulated in the treatment failure patients than the control group (p = 0.038016). miR-10a expression was up-regulated in newly diagnosed and treatment response patients compared to control group (p = 0.003934, p = 0.000292, respectively). It was found that miR-10a expression increased 11.17- fold in newly diagnosed patients and 9.82-fold in treatment response patients than in the control group. CONCLUSION: Our data suggest that expression profiles of miR-10a, miR-150, and miRNA 148b were correlated as biomarker and therapeutic tool in Turkish patients with CML (Tab. 2, Fig. 1, Ref. 30). Text in PDF www.elis.sk.eninfo:eu-repo/semantics/openAccessChronic myeloid leukemiaMicroRNAsNew diagnosisTreatment failureTreatment responseArticle1212159163WOS:0005089301000112-s2.0-850808404303211597110.4149/BLL_2020_023Q3Q3